chevron_leftBack
As of 14 June 2026, Filana Therapeutics, Inc. has a market cap of $69.56M USD, ranking #28148 globally and #4232 in the United States.
It ranks #2542 in the Healthcare sector, and #489 in the Biotechnology industry.
Key Stats
Market Cap
$69.56MUSD
Enterprise Value
-$20.14MUSD
EBITDA (TTM)
-$59.15MUSD
Net Income (TTM)
-$90.97MUSD
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Barry
open_in_new
Employees
20
Founded
1998
Website
filanatx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -7.7% | -15% | -13% | -29% | -59% | -8.8% |
News
Loading...
SAVA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SAVA
Cassava Sciences Inc
ISIN: US14817C1071
Shares Out.:
Shares Outstanding:
48.308M1
Shares Float:
42.647M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.44 USD | |
|
PX91
Cassava Sciences Inc
ISIN: US14817C1071
|
1.32 EUR | |
|
SAVA
Cassava Sciences Inc
ISIN: US14817C1071
|
56.00 MXN |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
262K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
230K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
40K%
|
-
|
|
NYSE: IQV
|
$26.3B
38K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
36K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
26K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
69K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
64K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
61K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
61K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
40K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
37K%
|
-
|
chevron_leftBack